226 related articles for article (PubMed ID: 1281393)
1. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O
Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393
[TBL] [Abstract][Full Text] [Related]
2. Relationship between cell-free viraemia, antigenaemia and antibody levels in HIV-1-infected Ethiopian patients.
Ayehunie S; Sönnerborg A; Desta B; Kefene H; Zewdie D; Britton S; Strannegård O
AIDS; 1992 Jul; 6(7):651-7. PubMed ID: 1503684
[TBL] [Abstract][Full Text] [Related]
3. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
St Clair MH; Martin JL; Tudor-Williams G; Bach MC; Vavro CL; King DM; Kellam P; Kemp SD; Larder BA
Science; 1991 Sep; 253(5027):1557-9. PubMed ID: 1716788
[TBL] [Abstract][Full Text] [Related]
4. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
Johnson VA; Merrill DP; Videler JA; Chou TC; Byington RE; Eron JJ; D'Aquila RT; Hirsch MS
J Infect Dis; 1991 Oct; 164(4):646-55. PubMed ID: 1716649
[TBL] [Abstract][Full Text] [Related]
5. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
Eron JJ; Chow YK; Caliendo AM; Videler J; Devore KM; Cooley TP; Liebman HA; Kaplan JC; Hirsch MS; D'Aquila RT
Antimicrob Agents Chemother; 1993 Jul; 37(7):1480-7. PubMed ID: 7689822
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Larder BA; Kohli A; Bloor S; Kemp SD; Harrigan PR; Schooley RT; Lange JM; Pennington KN; St Clair MH
J Virol; 1996 Sep; 70(9):5922-9. PubMed ID: 8709213
[TBL] [Abstract][Full Text] [Related]
7. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
Reichman RC; Tejani N; Lambert JL; Strussenberg J; Bonnez W; Blumberg B; Epstein L; Dolin R
Antiviral Res; 1993 Apr; 20(4):267-77. PubMed ID: 8097906
[TBL] [Abstract][Full Text] [Related]
8. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
Shirasaka T; Yarchoan R; O'Brien MC; Husson RN; Anderson BD; Kojima E; Shimada T; Broder S; Mitsuya H
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):562-6. PubMed ID: 8380641
[TBL] [Abstract][Full Text] [Related]
9. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
Gao Q; Gu ZX; Parniak MA; Li XG; Wainberg MA
J Virol; 1992 Jan; 66(1):12-9. PubMed ID: 1727474
[TBL] [Abstract][Full Text] [Related]
10. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
Gu Z; Gao Q; Li X; Parniak MA; Wainberg MA
J Virol; 1992 Dec; 66(12):7128-35. PubMed ID: 1279198
[TBL] [Abstract][Full Text] [Related]
11. Generation of nucleoside-resistant variants of HIV-1 by in vitro selection in the presence of AZT or DDI but no by combinations.
Gao Q; Parniak MA; Gu Z; Wainberg MA
Leukemia; 1992; 6 Suppl 3():192S-195S. PubMed ID: 1602823
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
13. [Investigation of AZT susceptibility of sequential HIV-1 isolates from patients treated with ddI after long-term therapy with AZT].
Saito T; Kondo M; Ito A; Nagao T; Hayashi T; Watanabe S; Imai M
Kansenshogaku Zasshi; 1994 Jul; 68(7):819-23. PubMed ID: 8089546
[TBL] [Abstract][Full Text] [Related]
14. Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.
McLeod GX; McGrath JM; Ladd EA; Hammer SM
Antimicrob Agents Chemother; 1992 May; 36(5):920-5. PubMed ID: 1510414
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations.
Cox SW; Apéria K; Albert J; Wahren B
AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1725-9. PubMed ID: 7888232
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
Periclou AP; Nandy P; Avramis VI
In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
[TBL] [Abstract][Full Text] [Related]
17. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
[TBL] [Abstract][Full Text] [Related]
18. Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.
Medina DJ; Hsiung GD; Mellors JW
Antimicrob Agents Chemother; 1992 May; 36(5):1127-30. PubMed ID: 1510405
[TBL] [Abstract][Full Text] [Related]
19. Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
Gao Q; Gu Z; Salomon H; Nagai K; Parniak MA; Wainberg MA
Arch Virol; 1994; 136(1-2):111-22. PubMed ID: 8002779
[TBL] [Abstract][Full Text] [Related]
20. Natural resistance of human immunodeficiency virus type 2 to zidovudine.
Reid P; MacInnes H; Cong ME; Heneine W; García-Lerma JG
Virology; 2005 Jun; 336(2):251-64. PubMed ID: 15892966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
